Market Trends of Germany Pharmaceutical Cold Chain Logistics Industry
Surge in Demand for Temperature-Controlled Solutions
Efficient and reliable logistics solutions for temperature-sensitive pharmaceutical products are increasingly in demand, underscoring the importance of proper storage and transportation in this sector. For example, the Budapest Branch, recently certified for Good Distribution Practice (GDP), is strategically located next to Liszt Ferenc International Airport. This prime location enhances its capability to manage air freight transport. The branch features a state-of-the-art temperature-controlled facility, offering dual storage zones: one set between 2°C to 8°C (refrigerated) and another maintaining a constant temperature of 15°C to 25°C. By merging NX Group's international temperature-controlled transport services with its storage solutions, the Group, as highlighted by Nippon Express Holdings in August 2024, has established a robust and premium platform for pharmaceutical logistics.
To cater to the pharmaceutical sector's transportation needs, there's a growing requirement for expanded capacities in refrigerated fleets. For instance, Petit Forestier, a cooling solutions provider, has introduced over 100 additional rental refrigerated vehicles in the 7.2, 12, and 18-ton classes, specifically targeting the German market.
Moreover, in August 2024, Parcel and Postal Technology International reported that Trans-o-flex and PostNL Pharma & Care Benelux have collaborated to integrate each other's temperature-controlled logistics solutions for the pharmaceutical industry, aiming to broaden their geographical presence. In conclusion, the pharmaceutical logistics sector is evolving rapidly, driven by the need for advanced temperature-controlled solutions. Strategic collaborations and expansions in refrigerated fleet capacities are essential to meet the growing demands and ensure the safe and efficient transport of pharmaceutical products.
Biopharmaceuticals to Contribute in Market Expansion
Biological medicines have significantly reshaped the landscape of the pharmaceutical industry. Germany, particularly its southern region, produces over half of the EU-approved active biopharmaceutical ingredients, solidifying its position as the leading producer in the European pharmaceutical market. For instance, Frigo-Trans, a German logistics provider, has unveiled its plans to build a cryopreservation warehouse at its Mutterstadt site.
Lake Constance and Ulm serve as the primary hubs for this activity. This small region is home to over 100 companies spanning biotech, pharmaceuticals, and medical technology, alongside various research organizations. While Germany has consistently held a prominent position within Europe, global rankings place it fifth in manufacturing capacity. This lag is largely attributed to other nations, bolstered by competitive tax structures, outpacing Germany in biopharmaceutical production investments. Nevertheless, biologics, given their remarkable therapeutic potential, have significantly expanded their foothold in Germany's pharmaceutical landscape.
Germany fosters a dynamic environment not just for general drug production but also for biopharmaceutical enterprises. Companies such as Vetter, Teva, Biberach Site, and Boehringer Ingelheim are at the forefront, introducing innovations that bolster the nation's pharmaceutical ambitions. Navigating these intricate markets, EuroDev has been a steadfast ally for North American producers, offering insights on market entry into Germany's pharmaceutical realm. Their expertise encompasses real-time guidance on prevailing regulations, market trends, competitive landscape, and potential challenges in the German pharmaceutical arena.
